Page last updated: 2024-11-04

rolipram and Cystitis

rolipram has been researched along with Cystitis in 2 studies

Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.

Research Excerpts

ExcerptRelevanceReference
"These results indicate that rolipram can attenuate the development of CYP-induced cystitis in rats by suppressing cytokine production and iNOS induction."7.75Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats. ( Kawakami, S; Kihara, K; Masuda, H; Matsuoka, Y; Sakura, M; Yokoyama, M, 2009)
"These results indicate that rolipram can attenuate the development of CYP-induced cystitis in rats by suppressing cytokine production and iNOS induction."3.75Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats. ( Kawakami, S; Kihara, K; Masuda, H; Matsuoka, Y; Sakura, M; Yokoyama, M, 2009)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sakura, M1
Masuda, H1
Matsuoka, Y1
Yokoyama, M1
Kawakami, S1
Kihara, K1
Büyüknacar, HS1
Kumcu, EK1
Göçmen, C1
Onder, S1

Other Studies

2 other studies available for rolipram and Cystitis

ArticleYear
Rolipram, a specific type-4 phosphodiesterase inhibitor, inhibits cyclophosphamide-induced haemorrhagic cystitis in rats.
    BJU international, 2009, Volume: 103, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cystitis; Female; Interleukin-1beta; N

2009
Effect of phosphodiesterase type 4 inhibitor rolipram on cyclophosphamide-induced cystitis in rats.
    European journal of pharmacology, 2008, May-31, Volume: 586, Issue:1-3

    Topics: Anesthesia; Animals; Antineoplastic Agents, Alkylating; Calcium Channel Blockers; Cyclophosphamide;

2008